INKT: MiNK Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $73K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | CEO | $73K |
Institutional ownership (Q2 2026)
28 institutions reported holding $2.39M of MiNK Therapeutics, Inc. on Form 13F (23 the quarter before). 8 opened a new position and 3 sold out. Shares held by institutions: +61%.
| Largest holders | Shares | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 68,660 | $803K |
| DNB Asset Management AS | 55,142 | $645K |
| Longbow Finance SA | 16,667 | $195K |
| GEODE CAPITAL MANAGEMENT, LLC | 15,573 | $182K |
| CITADEL ADVISORS LLC | 15,440 | $180K |
| BlackRock, Inc. | 13,382 | $156K |
| VANGUARD FIDUCIARY TRUST CO | 8,287 | $97K |
| UBS Group AG | 4,885 | $57K |
| Steward Partners Investment Advisory, LLC | 2,000 | $23K |
| US BANCORP \DE\ | 1,995 | $23K |
Clinical trial readouts
1 Phase 2 or 3 trials by MiNK Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-06 (est.) | agenT-797 | Pneumonia | Phase 2 | 90 | Recruiting | NCT07615010 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.